Trial Profile
A Randomized, Double-Blind Study With an Open-Label Extension Comparing the Effect of Once-Weekly Dulaglutide With Placebo in Pediatric Patients With Type 2 Diabetes Mellitus (AWARD-PEDS: Assessment of Weekly AdministRation of LY2189265 in Diabetes-PEDiatric Study)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Nov 2023
Price :
$35
*
At a glance
- Drugs Dulaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms AWARD-PEDS
- Sponsors Eli Lilly and Company
- 06 Oct 2023 Results of post-hoc analysis examining changes in laboratory measures of kidney function, glomerular hyperfltration, and albuminuria in youth with T2D treated with dulaglutide, presented at the 59th Annual Meeting of the European Association for the Study of Diabetes
- 23 Sep 2022 Results presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
- 07 Jun 2022 Results presented at the 82nd Annual Scientific Sessions of the American Diabetes Association